Fulgent Genetics, Inc. CFO Sells 346,252.38 in Stock

FLGT Stock  USD 18.85  0.10  0.53%   
Slightly above 67% of Fulgent Genetics' investor base is looking to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are alarmed at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
  
Fulgent Genetics, Inc. CFO Paul Kim sold 10,299 shares of Fulgent Genetics stock in a transaction dated Monday, August 28th. The stock was sold at an average price of 33.62, for a total transaction of 346,252.38. Following the transaction, the chief financial officer now owns 215,553 shares of the companys

Read at thelincolnianonline.com
news
  

Fulgent Genetics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Fulgent Genetics Maximum Pain Price Across January 17th 2025 Option Contracts

Fulgent Genetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Fulgent Genetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Fulgent Genetics' options.

Fulgent Genetics Fundamental Analysis

We analyze Fulgent Genetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

Fulgent Genetics is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Fulgent Genetics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fulgent Genetics stock to make a market-neutral strategy. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with similar companies.

Peers

Fulgent Genetics Related Equities

CDNACaredx   5.63   
0%
46.0%
NTRANatera   3.64   
0%
29.0%
GHGuardant Health   1.22   
0%
10.0%
ILMNIllumina   0.43   
0%
3.0%
TMOThermo Fisher   0.13   
1.0%
0%
AAgilent Technologies   0.30   
2.0%
0%
DHRDanaher   0.42   
3.0%
0%
MTDMettler Toledo   0.68   
5.0%
0%
EXASEXACT Sciences   0.74   
6.0%
0%
WATWaters   0.75   
6.0%
0%
CRLCharles River   0.97   
7.0%
0%
TWSTTwist Bioscience   1.10   
9.0%
0%
TTOOT2 Biosystms   12.20   
100.0%
0%

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.